AI assistant
Sending…
EyePoint Pharmaceuticals, Inc. — Director's Dealing 2022
Jul 13, 2022
32254_dirs_2022-07-13_166b7033-9f55-4d2f-82a0-1cc1e09ab438.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2022-07-11
Reporting Person: Zaderej Karen L. (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-07-11 | Restricted Stock Units | $0.00 | A | 6000.00 | Acquired | Common Stock (6000.00) | Direct | |
| 2022-07-11 | Stock Option (Right to Buy) | $8.22 | A | 22000.00 | Acquired | 2032-07-10 | Common Stock (22000.00) | Direct |
Footnotes
F1: The restricted stock units will vest in three equal annual installments beginning July 11, 2023.
F2: The option becomes exercisable in three ratable annual installments beginning on July 11, 2023.
More from EyePoint Pharmaceuticals, Inc.
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 6
Investor Presentation
2026
Apr 13
Director's Dealing
2026
Mar 24
Legal Proceedings Report
2026
Mar 20
Regulatory Filings
2026
Mar 4
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 18
Major Shareholding Notification
2026
Feb 12
Director's Dealing
2026
Jan 7